Land: Irland
Språk: engelsk
Kilde: HPRA (Health Products Regulatory Authority)
Diclofenac sodium
Lexon Pharmaceuticals (Ireland) Limited
D11AX18
Diclofenac sodium
3 percent weight/weight
Gel
diclofenac
2018-07-06
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: What Solaraze is and what it is used for What you need to know before you use Solaraze How to use Solaraze Possible side effects How to store Solaraze Contents of the pack and other information WHAT SOLARAZE IS AND WHAT IT IS USED FOR Solaraze is a non-steroidal anti-inflammatory dermatological gel. When applied to the skin, Solaraze gel is used to treat a skin problem known as actinic or solar keratosis that is caused by long-term sun exposure. WHAT YOU NEED TO KNOW BEFORE YOU USE SOLARAZE DO NOT USE SOLARAZE • If you are allergic to diclofenac or any of the ingredients of this medicine (listed in section 6). • If you have had an allergic reaction such as skin rash (nettle rash), breathing difficulties (wheezing) or runny nose (allergic rhinitis) after taking aspirin or any other non-steroidal anti-inflammatory agents. • If you are in the final 3 months of your pregnancy. WARNINGS AND PRECAUTIONS • The possibility of systemic side effects from application of Solaraze cannot be excluded if the product is used on large areas of skin and over a prolonged period. Consult your doctor if: - you have, or have had in the past, a stomach ulcer or bleeding from the stomach. - you have heart, liver or kidney problems. - you have any type of bleeding disorder or bruise very easily. • Avoid sun exposure, including tanning salons, when using Solaraze. If skin reactions occur, discontinue use. • Do not apply to skin wounds, infected skin or dermatitis. • D read_full_document
Health Products Regulatory Authority 26 September 2022 CRN00D4VZ Page 1 of 2 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Solaraze 3% gel 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each gram contains 30 mg diclofenac sodium (3% w/w). Excipient(s) with known effect: benzyl alcohol. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Gel _Product imported from Austria and Portugal_ A clear, transparent, colourless or pale yellow gel. 4 CLINICAL PARTICULARS As per PA0968/004/001 5 PHARMACOLOGICAL PROPERTIES As per PA0968/004/001 6 PHARMACEUTICAL PARTICULARS 6.1 LIST OF EXCIPIENTS Sodium hyaluronate Benzyl alcohol Macrogol monomethyl ether 350 Purified water 6.2 INCOMPATIBILITIES Not applicable. 6.3 SHELF LIFE The shelf life expiry date for this product shall be the date shown on the tube and outer package of the product on the market in the country of origin. Shelf life after opening: 6 months 6.4 SPECIAL PRECAUTIONS FOR STORAGE Do not store above 25 °C. 6.5 NATURE AND CONTENTS OF CONTAINER The product is supplied in a sealed tube with a white screw on cap with a pierced tip. Health Products Regulatory Authority 26 September 2022 CRN00D4VZ Page 2 of 2 Pack size: 50 g (2 x 25 g) size 6.6 SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING No special requirements. 7 PARALLEL PRODUCT AUTHORISATION HOLDER Lexon Pharmaceuticals (Ireland) Limited Block 3 Harcourt Centre Harcourt Road Dublin 2 Ireland 8 PARALLEL PRODUCT AUTHORISATION NUMBER PPA23176/021/001 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 6 th July 2018 10 DATE OF REVISION OF THE TEXT September 2022 read_full_document